Frauke Stascheit

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Burden of disease in myasthenia gravis: taking the patient’s perspective

Sophie Lehnerer, Jonas Jacobi, Ralph Schilling et al. · Journal of Neurology · 2021 · 164 citations · Full text

Medicine, Internal Medicine, Neurology +13

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Christopher Nelke, Frauke Stascheit, Carmen Eckert et al. · Journal of Neuroinflammation · 2022 · 127 citations · Full text

Nursing, Health Sciences, Clinical Epidemiology +7

Eculizumab versus rituximab in generalised myasthenia gravis

Christopher Nelke, Christina B. Schroeter, Frauke Stascheit et al. · Journal of Neurology Neurosurgery & Psychiatry · 2022 · 42 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Toxoplasma gondii seropositivity is negatively associated with multiple sclerosis

Frauke Stascheit, Friedemann Paul, Lutz Harms et al. · Journal of Neuroimmunology · 2015 · 34 citations

Life Sciences, Immunology, Neurology +12